<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079794</url>
  </required_header>
  <id_info>
    <org_study_id>R21AT001020-01</org_study_id>
    <secondary_id>Rosenzweig</secondary_id>
    <nct_id>NCT00079794</nct_id>
  </id_info>
  <brief_title>Iscar for Supplemental Care in Stage IV Lung Cancer</brief_title>
  <official_title>Iscar for Supplemental Care in Stage IV Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Center for Complementary and Integrative Health (NCCIH)</source>
  <brief_summary>
    <textblock>
      The purpose of this study it to determine whether supplemental treatment with Iscar improves
      immune function and quality of life among Stage IV non-small cell lung carcinoma patients
      receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant
      extract of mistletoe. this preparation is already in use in Europe and its use in the US is
      likely to increase as cancer patients continue to seek alternative therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See Brief Summary
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>36</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iscar</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mistletoe</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage IV NSCLC patients who receive standard chemotherapy

        Exclusion criteria:

          -  Known allergy to Viscum Album L.

          -  Concomitant use of other mistletoe products

          -  Concomitant use of mushroom glucan and proteoglycan extracts

          -  Concomitant use of thymus extract products

          -  Inability to self-report quality of life utilizing assessment tools

          -  Ongoing steroid or ACTH therapy

          -  Co-morbid immunocompromised state

          -  Pregnancy

          -  Participation in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Rosenzweig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jefferson Medical College of Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2004</study_first_submitted>
  <study_first_submitted_qc>March 15, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2004</study_first_posted>
  <last_update_submitted>January 23, 2008</last_update_submitted>
  <last_update_submitted_qc>January 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2008</last_update_posted>
  <keyword>lung cancer</keyword>
  <keyword>herbal medicine</keyword>
  <keyword>non-small cell cancer</keyword>
  <keyword>Iscar</keyword>
  <keyword>mistletoe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

